BCR-ABL mutations detected in DASISION participants
| . | Dasatinib . | Imatinib . |
|---|---|---|
| Discontinued study treatment, n (%) | 59 (23) | 64 (25) |
| Mutation assay performed, n | 44 | 49 |
| BCR-ABL mutation detected | 10 | 10 |
| No BCR-ABL mutation detected | 28 | 38 |
| Insufficient BCR-ABL cDNA amplified | 6 | 1 |
| . | Dasatinib . | Imatinib . |
|---|---|---|
| Discontinued study treatment, n (%) | 59 (23) | 64 (25) |
| Mutation assay performed, n | 44 | 49 |
| BCR-ABL mutation detected | 10 | 10 |
| No BCR-ABL mutation detected | 28 | 38 |
| Insufficient BCR-ABL cDNA amplified | 6 | 1 |
Evaluation of BCR-ABL mutations was stipulated by the protocol in patients who discontinued study treatment for any reason.
DASISION indicates DASatinib versus Imatinib Study In treatment-Naive CML patients.